More on AVIR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.27 |
|
|||
| Open | $4.25 | ||||
| 52 Wk High | $2.00 | ||||
| 52 Wk Low | $1.15 | ||||
| Day High | $4.31 | ||||
| Day Low | $4.16 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 330,216 | ||||
- Atea presents drug interaction data for hepatitis C treatment
- Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL C
- Form 4/A Atea Pharmaceuticals, For: May 18 Filed by: Murphy Polly A.
- Form 4 Atea Pharmaceuticals, For: May 18 Filed by: Murphy Polly A.
- Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
- Form 10-Q Atea Pharmaceuticals, For: Mar 31
- Aviragen Therapeutics (AVIR) Misses Q1 EPS by 1c
- Form 8-K Atea Pharmaceuticals, For: May 12
- Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- Form SCHEDULE 13G/A Atea Pharmaceuticals, Filed by: FMR LLC
Entities mentioned with AVIR
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Stifel | View Related Stories »
- Show More...
